Amgen, Inc. vs Bank of Montreal — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Bank of Montreal trades at $182.04 (market cap $126.83B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Bank of Montreal pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| AMGN | BMO | |
|---|---|---|
Market Cap | $224.14B | $126.83B |
Sector | Health | Financials |
52-Week High | $417.20 | $183.65 |
52-Week Low | $271.18 | $112.54 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 2.69% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →